Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP@STAH: Semaglutide for Antipsychotic-Induced Weight Gain
NCT06754163Phase 4Active, not recruiting
- Sponsor
- St Andrew's Healthcare
- Start
- Jan 2025
- Primary completion
- Jul 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of semaglutide in obesity, sponsored by St Andrew's Healthcare. Started Jan 2025; status: active, not recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06754163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06754163.